Journal: Urology
Article Title: Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy.
PMID/MRN: 27816603
Publication Date: 2016-Nov-02
Abstract:
To characterize the incidence, presentation, management, and relapse of a large population of bilateral testicular germ cell tumors (TGCT) from a single institution.
We identified bilateral TGCT diagnosed between 1/1989 and 2/2014. We categorized synchronous and metachronous TGCT, noting time between 1 st and 2 nd TGCT, histology [seminoma vs. nonseminoma (NSGCT)], stage and treatments. Kaplan Meier survival estimates characterized relapse.
Of 5,132 TGCT patients, 128 (2.5%) had bilateral TGCT. Bilateral TGCT increased over time-1.7% in 1989-1994 up to 3.8% in 2010-2/2014. The 35 (27%) synchronous TGCT had 20 (57%) concordant seminoma, 5 (14%) concordant NSGCT, and 10 (29%) discordant. The 93 (73%) metachronous cases had median time interval to 2nd TGCT of 73 months (range 5 months to 28.6 years). Compared to 1 st TGCT, 39 (42%) had discordant histology, 29 (31%) concordant seminoma, and 25 (27%) concordant NSGCT. Stage at 1 st tumor was statistically similar to second TGCT (2 nd stage I/II/II in 69%/22%/10%). Increasing duration between 1 st and 2nd TGCT was not associated with higher stage (II/III) at second TGCT (p=0.09). Treatment at 1 st tumor was not associated with stage at 2 nd tumor. Relapse following bilateral diagnosis was 16.8% (95%CI 10.5-26.2%) at 5 years.
Incidence of bilateral TGCT increased with >25% of metachronous TGCT presenting ³10 years after 1st TGCT; possible causes include increased survivorship and/or referral bias. Stage was statistically similar at 1 st and 2 nd tumor; stage at 2 nd tumor was not associated with time interval between tumors or prior treatment modality at 1 st tumor.
Copyright © 2016. Published by Elsevier Inc.